Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Chronic Lymphocytic Leukemia (Nov 2020)

Posted by Matt Breese on Nov 6, 2020

Find me on:

According to our recent payer coverage analysis for chronic lymphocytic leukemia (CLL) treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for CLL treatments shows that under the pharmacy benefit, almost 51% of the lives under commercial formularies are covered with utilization management restrictions.

MMIT-Reality Check-CLL-4Q2020-finalData snapshot as of Q4 2020

Trends: In April 2020, the FDA expanded the label for Pharmacyclics LLC, an AbbVie Inc. company, and Janssen Biotech, Inc.’s Imbruvica (ibrutinib) in combination with rituximab for the treatment of adults newly diagnosed with chronic lymphocytic leukemia or small lymphocytic leukemia.  

To read the full Reality Check on Chronic Lymphocytic Leukemia treatments with key findings on clinical characteristics, drug market access and payer coverage, please click on the button below: 


View Reality Check

Topics: Specialty, Market Access, Payer, Branding & Marketing